G1 Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
G1 Therapeutics, Inc. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include COSELA, G1 TO ONE, and G1 THERAPEUTICS. The owner is based in Research Triangle Park, NC.
700 Park Offices Drive, Suite 200
Research Triangle Park, NC 27709
Showing of trademarks Trademarks
Trademark Classifications
G1 Therapeutics, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Insurance; financial affairs; monetary affairs; real estate affairs
Frequently Asked Questions
How many trademarks does G1 Therapeutics, Inc. have?
G1 Therapeutics, Inc. has 6 U.S. trademarks filed with the USPTO. Of these, 6 registered.
What trademark classes does G1 Therapeutics, Inc. file in?
G1 Therapeutics, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 36 (Insurance & Financial). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are G1 Therapeutics, Inc.'s most well-known trademarks?
G1 Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as COSELA, G1 TO ONE, and G1 THERAPEUTICS. These are among 6 currently registered trademarks in the portfolio.
What is G1 Therapeutics, Inc.'s trademark registration success rate?
G1 Therapeutics, Inc. has a 100% trademark registration rate, with 6 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.